New Mexico § 59A-59A-7 Superintendent of insurance legislative reports

New Mexico Statutes

§ 59A-59A-7 — Superintendent of insurance legislative reports

New Mexico § 59A-59A-7

Ch. 59AInsurance Code

Art. 59APrescription Drug Price Transparency

This text of New Mexico § 59A-59A-7 (Superintendent of insurance legislative reports) is published on Counsel Stack Legal Research, covering New Mexico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

N.M. Stat. Ann. § 59A-59A-7 (2026).

Text

A. By December 31, 2025, and annually thereafter, the superintendent shall submit to the legislative finance committee and the legislative health and human services committee a report that includes:

(1)aggregate market trends for prescription drug products across the state and country;

(2)the impact of prescription drug product prices in the state, including the overall impact of prescription drug product costs on health care premiums;

(3)the geographic and demographic populations in the state most affected by high prescription drug product costs; and (4) any recommendations the superintendent has on further action or legislation needed to make prescription drug products more affordable and reduce overall patient cost in the state. B. By December 31, 2025, and annually thereafter, the s

Free access — add to your briefcase to read the full text and ask questions with AI

A. By December 31, 2025, and annually thereafter, the superintendent shall submit to the legislative finance committee and the legislative health and human services committee a report that includes: (1) aggregate market trends for prescription drug products across the state and country; (2) the impact of prescription drug product prices in the state, including the overall impact of prescription drug product costs on health care premiums; (3) the geographic and demographic populations in the state most affected by high prescription drug product costs; and (4) any recommendations the superintendent has on further action or legislation needed to make prescription drug products more affordable and reduce overall patient cost in the state. B. By December 31, 2025, and annually thereafter, the superintendent shall aggregate the information collected from manufacturers, pharmacy services administrative organizations, authorized health insurers and pharmacy benefits managers and submit a report on the aggregate data to the legislative finance committee and the legislative health and human services committee. The superintendent shall hold an annual public meeting that is focused on discussing the contents of the report. C. The superintendent shall make the reports required by this section available to the public on the superintendent's website. D. The aggregate data included in the reports shall not disclose or tend to disclose proprietary or confidential information on any specific or individual manufacturer, pharmacy services administrative organization, authorized health insurer, pharmacy benefits manager or consumer.